Navigation Links
Soligenix to Present at 8th Annual BIO Investor Forum
Date:10/27/2009

bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM(TM) are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's mo
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
2. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. Transdel Pharmaceuticals to Present at Two Investor Conferences
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE
8. Advanced Life Sciences to Present at 8th Annual BIO Investor Forum
9. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
10. China Pharma Holdings, Inc. to Present at the Roth China Conference on October 14 at 12:00 pm ET
11. 17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ITRA Global, ... and occupiers of commercial real estate, has further expanded ... offices in Perth and Brisbane, Western Australia, reports Mylinda ... directors. , ITRA Global / ACORPP (Australian Corporate ... independent consultancy company providing property services to a wide ...
(Date:12/19/2014)... -- Naurex Inc., a biopharmaceutical company leveraging its unique ... central nervous system, today announced that Norbert Riedel ... at the 33 rd annual J.P. Morgan Healthcare ... p.m. PST on Tuesday, January 13, 2015, at the ... About Naurex Inc. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... 11 Olympus has further,cemented its position as a ... an exclusive and immediate deal to distribute the products ... sole global,provider of ports for state-of-the-art laparoscopic operative techniques ... is now the exclusive,distributor for the full range of ...
... THOUSAND OAKS, Calif., Dec. 11 Ceres, Inc. announced ... seed under its,Blade Energy Crops label. The highly anticipated ... developed specifically as raw materials,for biofuels and biopower. The ... , The company ...
... Delcath Systems, Inc. (Nasdaq: DCTH ), ... ("PHP") System for the treatment of cancers of the liver, ... of patients have been enrolled in the Phase III clinical ... The eleven participating cancer centers in this trial continue ...
Cached Biology Technology:Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2First Seed Sales of Dedicated Energy Crops Begin 2First Seed Sales of Dedicated Energy Crops Begin 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... It,s illegal for health products with medical formulations to be ... on animals ― a situation that has serious ethical and ... by Prof. Amit Gefen of Tel Aviv University,s Faculty of ... be needed for the necessary experimental trials. Dr. Gefen,s ...
... The six sponsoring societies for the meeting ... The American Physiological Society, American Society for Biochemistry ... American Society for Nutrition, and American Society for ... some of the science being presented April 24-28, ...
... genetically engineered (GE) crops are realizing substantial economic and ... pest problems, reduced use of pesticides, and better yields ... from the National Research Council. However, GE crops ... in Roundup and other commercial weed killers -- could ...
Cached Biology News:A lab rat -- created in the lab 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 3Selected highlights of the research being presented at the Experimental Biology 2010 meeting 4Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective 2Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective 3Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective 4
Complement factor B (human)...
... (c-Jun NH2-terminal kinase) signal transduction cascade ... kinase pathways in mammals. JNK pathway ... stress, is associated with the nuclear ... implicated in the immune response, cellular ...
... The Excalibur™ mid-, near- and far-infrared ... truly research-grade performance in their class. Yet ... price. Features: Highest-energy throughput: Having ... the source compared to other conventional FT-IRs ...
... Jobin Yvons Protein 295 ex can measure ... sample in only a few minutes. To ... acids tyrosine and tryptophan, the Protein 295 ... a pulsed diode emitting 295 nm. Fluorescence ...
Biology Products: